Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Industry Needs Pricing System That Rewards Innovation: JPMA President Dr Aoki
January 14, 2008
- GMP for Investigational Drugs to Be Amended
January 14, 2008
- JAPhMed to Certify Pharmaceutical Medicine Specialists
January 14, 2008
- REGULATORY NEWS IN BRIEF
January 14, 2008
- Complete Lifting of Ban on Kongyo Shinryo Not Recommended by Council
January 14, 2008
- Non-Tamiflu Users Show Higher Incidence of Abnormal Behavior: Study Team Report
January 14, 2008
- ON THE MOVE／J&J Appoints D. W. Powell President
January 14, 2008
- Abnormal Behavior Reported in 38% of Patients Not Taking Tamiflu
January 14, 2008
- R&D NEWS IN BRIEF
January 14, 2008
- Nexavar, Licomodulin, Zevalin to Be Officially Approved Soon
January 14, 2008
- Korosho's General Account Budget to Total \22,117.9 Bil.
January 14, 2008
- Korosho to Promote the Use of Generics by Welfare Recipients
January 14, 2008
- Rules to Be Revised to Oblige Pharmacists to Dispense Generics: Mr Urushibata
January 14, 2008
- Only 16% of Consumers Ask Doctors for Generics Despite High Awareness Rate
January 14, 2008
- Isoconazole, Emedastine to Be Switched to OTC
January 7, 2008
- AstraZeneca to Revise Invoice Prices as Market Conditions Change
January 7, 2008
- R&D NEWS IN BRIEF
January 7, 2008
- aRigen Licenses ARB-CF0223 to Axentis
January 7, 2008
- Takeda Initiates PIII Program for Lu AA21004
January 7, 2008
- Otsuka Acquires IV Busulfex from PDL BioPharma
January 7, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…